Myrna Candelaria

A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors

Myrna Candelaria, Dolores Gallardo‐Rincón, Claudia Arce et al. · Annals of Oncology · 2007 · 249 citations

Chemotherapy Resistance, Medicine, Pharmacology +7

A Proof-Of-Principle Study of Epigenetic Therapy Added to Neoadjuvant Doxorubicin Cyclophosphamide for Locally Advanced Breast Cancer

Claudia Arce, Carlos Pérez‐Plasencia, Aurora González‐Fierro et al. · PLoS ONE · 2006 · 144 citations · Full text

Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines

Alma Chávez‐Blanco, Carlos Pérez‐Plasencia, Enrique Pérez‐Cárdenas et al. · Cancer Cell International · 2006 · 142 citations · Full text

A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results

Jaime Coronel, Lucely Cetina, Irlanda Pacheco et al. · Medical Oncology · 2010 · 131 citations

Advanced Cervical Cancer, Cervical Cancer, Medicine +10

Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study

Alma Chávez‐Blanco, Blanca Segura-Pacheco, Enrique Pérez‐Cárdenas et al. · Molecular Cancer · 2005 · 127 citations · Full text